H1’FY27 Revenue from Operations grows by 28.7% YoY to INR 1,269 Crores H1’FY27 EBITDA grows by 27.0% YoY to INR 362 Crores
H1’FY27 PAT grows by 50.1% YoY to INR 112 Crores
Chennai: Dr. Agarwal’s Health Care Limited (NSE: AGARWALEYE, BSE: 544350), India’s largest eye care service chain(1) operating a network of 305 facilities across India and 19 facilities across Africa, today announced its unaudited consolidated financial results for the half year ended September 30, 2026.
Highlights for the Quarter Ended September 30, 2026 (Q2’FY27)
- As of September 30, 2026, our network stands at 324 facilities, with 21 new centres added during the quarter comprising 1 tertiary, 17 secondary and 3 primary facilities
- Performed 95,841 surgeries during the quarter, growth of 22.2% YoY
- Total Income of INR 665 Crores; growth of 31.3% YoY
- Revenue from Operations of INR 655 Crores; growth of 31.4% YoY
- Revenue from Operations – India of INR 586 Crores, growth of 31.6% YoY
- 18.8% Same Store Sales Growth (SSSG) in Q2’FY27 across all facilities set up or acquired up to H1’FY24
- Sale of Services(2) contributed 78.0% and Sale of Products(2) contributed 22.0% to revenue from operations
- EBITDA of INR 186 Crores, growth of 28.8% YoY with EBITDA margins of 27.9%
- Profit after Tax of INR 57 Crores, growth of 55.8% YoY with PAT margins of 8.5%
Highlights for the Half Year Ended September 30, 2026 (H1’FY27)
- As of September 30, 2026, our network stands at 324 facilities, with 39 new centres added during the half year comprising 3 tertiary, 31 secondary and 5 primary facilities
- Performed 186,923 surgeries during the half year, growth of 18.8% YoY
- Total Income of INR 1,286 Crores; growth of 27.6% YoY
- Revenue from Operations of INR 1,269 Crores; growth of 28.7% YoY
- Revenue from Operations – India of INR 1,138 Crores, growth of 28.5% YoY
- 17.7% Same Store Sales Growth (SSSG) in H1’FY27 across all facilities set up or acquired up to H1’FY24
- Sale of Services(2) contributed 77.9% and Sale of Products(2) contributed 22.1% to revenue from operations
- EBITDA of INR 362 Crores, growth of 27.0% YoY with EBITDA margins of 28.2%
- Profit after Tax of INR 112 Crores, growth of 50.1% YoY with PAT margins of 8.7%
Commenting on the results, Dr. Adil Agarwal, CEO, Dr. Agarwal’s Health Care Limited, said: “The first half of FY27 has been a defining period for us, marked by strong growth across our key metrics. Revenue from Operations grew 28.7% year-on-year to INR 1,269 Crores, and Q2 was our highest-ever quarter at INR 655 Crores. Our mature hospitals continue to lead this growth, with same-store sales growth of 17.7%. EBITDA rose 27.0% to INR 362 Crores despite the investment in new centres, and Profit after Tax grew 50.1% to INR 112 Crores.
We added 39 facilities during the half year, taking our network to 324 facilities across India and Africa. In the first half alone, we added more surgical facilities than in all of FY26. We served over 18.4 lakh patients, up 28.5%, and performed c.1.87 lakh surgeries, up 18.8%, supported by a team of 1,100+ doctors. Patients are also increasingly choosing advanced care, with high-end surgeries contributing ~30% of cataract volumes.
Beyond these numbers, we continue to push the frontier of eye care. I am pleased to share that we have now opened the world’s first dedicated Pinhole Pupilloplasty (PPP) centre at our Chennai flagship facility. It is a proud milestone for Dr. Agarwal’s and reflects our commitment to clinical innovation. We now intend to take PPP across our network and globally, so that many more patients can benefit from it.”
(1) Based on Revenue from Operations for FY25, as per Crisil Intelligence
(2) Services include Surgeries, Consultation, Treatments and Investigations; Products include Opticals, Contact Lens and Accessories, and Pharmaceutical Products; Excludes other operating revenue
Consolidated Performance Highlights:
| Half Year Ended | Quarter Ended | |||||
| (In Cr) | H1’FY27 H1’FY26 YoY Growth (%) | Q2’FY27 Q2’FY26 YoY Growth (%) | ||||
| Revenue From Operations | 1,269 | 986 | 28.70% | 655 | 499 | 31.40% |
| Total Income | 1,286 | 1,007 | 27.60% | 665 | 507 | 31.30% |
| EBITDA | 362 | 285 | 27.00% | 186 | 144 | 28.80% |
| EBITDA Margin (%) | 28.20% | 28.30% | 27.90% | 28.40% | ||
| Profit After Tax | 112 | 75 | 50.10% | 57 | 36 | 55.80% |
| PAT Margin (%) | 8.70% | 7.40% | 8.50% | 7.20% | ||
Leave a Reply